Cover Image
市場調查報告書

TaiGen Biotechnology Co., Ltd.的產品平台分析

TaiGen Biotechnology Co., Ltd. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 251638
出版日期 內容資訊 英文 32 Pages
訂單完成後即時交付
價格
Back to Top
TaiGen Biotechnology Co., Ltd.的產品平台分析 TaiGen Biotechnology Co., Ltd. - Product Pipeline Review - 2015
出版日期: 2015年08月26日 內容資訊: 英文 32 Pages
簡介

TaiGen Biotechnology Co., Ltd.是總公司位於台灣的生物科技企業,專門研究開發並生產治療感染疾病、癌症、糖尿病相關併發症之新藥。

本報告提供TaiGen Biotechnology Co., Ltd.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

TaiGen Biotechnology Co., Ltd.的基本資料

  • TaiGen Biotechnology Co., Ltd.概要
  • 主要資訊
  • 企業資料

TaiGen Biotechnology Co., Ltd.:R&D概要

  • 主要的治療範圍

TaiGen Biotechnology Co., Ltd.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

TaiGen Biotechnology Co., Ltd.:開發中產品概況

  • 後期階段產品開發中產品
    • 新藥登記前階段的產品/聯合治療模式
    • 第三階段的產品/聯合治療模式
  • 臨床階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 藥物研發中的產品/聯合治療模式

TaiGen Biotechnology Co., Ltd.:藥物簡介

  • nemonoxacin
  • burixafor
  • TG-2349
  • Drug for Gram-Negative Bacterial Infections
  • Small Molecules for Influenza

TaiGen Biotechnology Co., Ltd.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

TaiGen Biotechnology Co., Ltd.:最新的開發平台資訊

TaiGen Biotechnology Co., Ltd.:開發暫停中的計劃

TaiGen Biotechnology Co., Ltd.:總公司和子公司的所在地

  • 總公司
  • 分公司及子公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07473CDB

Summary

Global Markets Direct's, 'TaiGen Biotechnology Co., Ltd. - Product Pipeline Review - 2015', provides an overview of the TaiGen Biotechnology Co., Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of TaiGen Biotechnology Co., Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of TaiGen Biotechnology Co., Ltd. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of TaiGen Biotechnology Co., Ltd.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the TaiGen Biotechnology Co., Ltd.'s pipeline products

Reasons to buy

  • Evaluate TaiGen Biotechnology Co., Ltd.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of TaiGen Biotechnology Co., Ltd. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the TaiGen Biotechnology Co., Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of TaiGen Biotechnology Co., Ltd. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of TaiGen Biotechnology Co., Ltd.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of TaiGen Biotechnology Co., Ltd. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • TaiGen Biotechnology Co., Ltd. Snapshot
    • TaiGen Biotechnology Co., Ltd. Overview
    • Key Information
    • Key Facts
  • TaiGen Biotechnology Co., Ltd. - Research and Development Overview
    • Key Therapeutic Areas
  • TaiGen Biotechnology Co., Ltd. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • TaiGen Biotechnology Co., Ltd. - Pipeline Products Glance
    • TaiGen Biotechnology Co., Ltd. - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • TaiGen Biotechnology Co., Ltd. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • TaiGen Biotechnology Co., Ltd. - Early Stage Pipeline Products
      • Discovery Products/Combination Treatment Modalities
  • TaiGen Biotechnology Co., Ltd. - Drug Profiles
    • nemonoxacin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • burixafor
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • furaprevir
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Gram-Negative Bacterial Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Influenza
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • TaiGen Biotechnology Co., Ltd. - Pipeline Analysis
    • TaiGen Biotechnology Co., Ltd. - Pipeline Products by Target
    • TaiGen Biotechnology Co., Ltd. - Pipeline Products by Route of Administration
    • TaiGen Biotechnology Co., Ltd. - Pipeline Products by Molecule Type
    • TaiGen Biotechnology Co., Ltd. - Pipeline Products by Mechanism of Action
  • TaiGen Biotechnology Co., Ltd. - Recent Pipeline Updates
  • TaiGen Biotechnology Co., Ltd. - Dormant Projects
  • TaiGen Biotechnology Co., Ltd. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • TaiGen Biotechnology Co., Ltd., Key Information
  • TaiGen Biotechnology Co., Ltd., Key Facts
  • TaiGen Biotechnology Co., Ltd. - Pipeline by Indication, 2015
  • TaiGen Biotechnology Co., Ltd. - Pipeline by Stage of Development, 2015
  • TaiGen Biotechnology Co., Ltd. - Monotherapy Products in Pipeline, 2015
  • TaiGen Biotechnology Co., Ltd. - Pre-Registration, 2015
  • TaiGen Biotechnology Co., Ltd. - Phase III, 2015
  • TaiGen Biotechnology Co., Ltd. - Phase II, 2015
  • TaiGen Biotechnology Co., Ltd. - Phase I, 2015
  • TaiGen Biotechnology Co., Ltd. - Discovery, 2015
  • TaiGen Biotechnology Co., Ltd. - Pipeline by Target, 2015
  • TaiGen Biotechnology Co., Ltd. - Pipeline by Route of Administration, 2015
  • TaiGen Biotechnology Co., Ltd. - Pipeline by Molecule Type, 2015
  • TaiGen Biotechnology Co., Ltd. - Pipeline Products by Mechanism of Action, 2015
  • TaiGen Biotechnology Co., Ltd. - Recent Pipeline Updates, 2015
  • TaiGen Biotechnology Co., Ltd. - Dormant Developmental Projects,2015
  • TaiGen Biotechnology Co., Ltd., Subsidiaries

List of Figures

  • TaiGen Biotechnology Co., Ltd. - Pipeline by Top 10 Indication, 2015
  • TaiGen Biotechnology Co., Ltd. - Pipeline by Stage of Development, 2015
  • TaiGen Biotechnology Co., Ltd. - Monotherapy Products in Pipeline, 2015
  • TaiGen Biotechnology Co., Ltd. - Pipeline by Top 10 Target, 2015
  • TaiGen Biotechnology Co., Ltd. - Pipeline by Top 10 Route of Administration, 2015
  • TaiGen Biotechnology Co., Ltd. - Pipeline by Top 10 Molecule Type, 2015
  • TaiGen Biotechnology Co., Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top